RxDoctor Payments Data

Anna Dzilenski, APRN

Nurse Practitioner · Cheshire, CTNPI 1669131116

Payments from drug & device makers

$1,240in general payments, 2019–2025

Across 61 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$472
  • Teva Pharmaceuticals USA, Inc.$378
  • AbbVie$130
  • Kyowa Kirin, Inc.$81
  • Neurocrine Biosciences, Inc.$63
  • Azurity Pharmaceuticals, Inc.$43
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$1,240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,240 in reported general payments places this provider in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$84,005
Medicare patients
336
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate113$569,156
IngrezzaValbenazine Tosylate59$483,337
RytaryCarbidopa/Levodopa232$349,355
GocovriAmantadine Hcl74$320,755
NourianzIstradefylline61$143,931
OngentysOpicapone137$111,648
HorizantGabapentin Enacarbil83$95,366
InbrijaLevodopa20$55,535
NeuproRotigotine25$41,207
LinzessLinaclotide43$31,555
Carbidopa-LevodopaCarbidopa/Levodopa729$28,681
BelsomraSuvorexant36$16,490
Stalevo 100Carbidopa/Levodopa/Entacapone12$14,143
Carbidopa-Levodopa ErCarbidopa/Levodopa322$13,966
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone31$10,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$63$594,985196 claims
MDD US Operations, LLCGocovri$472$320,75574 claims
Kyowa Kirin, Inc.Nourianz$81$143,93161 claims
AbbVieLinzess$130$31,55543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Cheshire

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →